Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...

Adrenergic Agonists: Direct-Acting Agents

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mobile App-Based Interactive Care Plan for Migraine: Survey Study of Usability and Improvement Opportunities.

JMIR formative research·2025

Same author

Causes of Intracranial Hypotension: Spontaneous, Traumatic, and Iatrogenic Cerebrospinal Fluid Leaks.

Neuroimaging clinics of North America·2024

Same author

Improving Neurology Inpatient Fall Rate: Effect of a Collaborative Interdisciplinary Quality Improvement Initiative.

Mayo Clinic proceedings. Innovations, quality & outcomes·2023

Same author

Current Understanding of the Pathophysiology and Approach to Tension-Type Headache.

Current neurology and neuroscience reports·2021

Same author

Interstitial amyloidosis in sporadic inclusion body myositis.

Muscle & nerve·2021

Same author

First Bite Syndrome: What Neurologists Need to Know.

Current pain and headache reports·2021

Same journal

Preface.

Handbook of clinical neurology·2026

Same journal

Foreword.

Handbook of clinical neurology·2026

Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026

Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026

Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026

Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

5-HT1F agonists.

Stephanie J Steel¹

¹Department of Neurology, Mayo Clinic, Rochester, MN, United States.

Handbook of Clinical Neurology

|February 2, 2024

Summary

This summary is machine-generated.

Selective 5-HT1F agonists, like lasmiditan, offer migraine relief without vasoconstriction, benefiting specific patients. However, CNS side effects and driving restrictions may limit their use.

Keywords:

Lasmiditan Migraine Rescue therapy Serotonin agonists Trigeminal ganglia

More Related Videos

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

Related Experiment Videos

Last Updated: Jul 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

Area of Science:

Pharmacology
Neurology
Medicinal Chemistry

Background:

Serotonin receptor agonism is a known mechanism for triptan migraine medications.
Selective 5-HT1F receptor agonists represent a newer class of migraine therapeutics.
The precise mechanism of action for 5-HT1F agonists in reducing acute migraine symptoms is still under investigation.

Conclusions:

Selective 5-HT1F agonists provide a novel therapeutic option for acute migraine treatment.
Lasmiditan's unique profile makes it suitable for specific patient populations.
Further consideration of side effects and usage restrictions is necessary for optimal clinical application.